{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:32:02Z","timestamp":1794047522692,"version":"4.8.0"},"reference-count":0,"publisher":"Ferrata Storti Foundation (Haematologica)","license":[{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>We report the final analysis of the Drep-Haplo multicenter phase 2 protocol, which evaluated haploidentical transplantation after reduced-intensity conditioning regimen incorporating thiotepa, in children and adults with severe sickle cell disease (SCD). Twenty-two patients (median age: 17 years; range: 12\u201340) received a conditioning regimen consisting of 2 Gy total body irradiation, thymoglobulin, cyclophosphamide, fludarabine, and thiotepa, followed by T cell\u2013replete bone marrow infusion and graft-versus-host disease (GVHD) prophylaxis based on post-transplant cyclophosphamide.\nThe primary endpoint, event-free survival, defined as survival without graft failure and without moderate-to-severe chronic GVHD, was 68.18% (95% CI: 51.25%\u201390.70%) and 61.98% (95% CI: 44.07%\u201387.19%) at 1 and 4 years, respectively. Overall survival and rejection-free survival at 4 years were 90.15% (95% CI: 78.03%\u2013100%) and 85.56% (95% CI: 71.63%\u2013100%), respectively. Six patients (27%) developed moderate-to-severe GVHD. In most cases (4\/6), GVHD resolved, leaving only two patients (9%) with persistent moderate to severe GVHD at last follow-up. Eighty-five grade 2 to 4 infectious episodes were reported in 21 patients during the 24 months of follow-up, most of which were bacterial (38 cases). These data strengthen existing evidence supporting the feasibility of haploidentical transplantation in both pediatric and adult patients with severe SCD, demonstrating a very low rejection rate when thiotepa is incorporated into the conditioning regimen. Future efforts should focus on reducing chronic GVHD and infection rates.<\/jats:p>","DOI":"10.3324\/haematol.2025.300013","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T08:57:48Z","timestamp":1765443468000},"source":"Crossref","is-referenced-by-count":1,"title":["HLA-haploidentical hematopoietic stem cell transplantation in patients with sickle cell disease: results from the phase II DREP-HAPLO trial"],"prefix":"10.3324","author":[{"given":"Nathalie","family":"Dhedin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedicte","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Paillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erasti","family":"Gounfle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nimnrod","family":"Buchbinder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Ouachee","family":"Chardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mabel","family":"Gaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Benoit","family":"Arlet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecile","family":"Arnaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Pondarre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2025,12,11]]},"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/13048\/79187","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/13048\/79187","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:10:35Z","timestamp":1794046235000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/13048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":0,"URL":"https:\/\/doi.org\/10.3324\/haematol.2025.300013","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,11]]}}}